THIS MONTH IN

JNM

Discussions with leaders: *JNM* editor in chief, Johannes Czernin, MD, conducts an interview with Hedvig Hricak on her experience as a long-time department chair and solicits her perspective on leadership, technologic innovation, and the future of nuclear medicine. . . . . ***Page 1038***

AI in nuclear cardiology: Gomez and Doukky provide perspective on the potential for artificial intelligence technologies, including machine learning, in enhancing risk prediction in nuclear cardiology. . . . . . . ***Page 1042***

Dedicated brain PET: Catana offers a state-of-the-art overview of current PET devices specifically designed for imaging the human brain, including performance characteristics, inclusion of other modalities, and goals for future-generation instrumentation. . . . . ***Page 1044***

^{18}F-FET PET after brain tumor surgery: Marner and colleagues ask whether additional postoperative ^{18}F-FET PET in children and adolescents with brain tumors can improve diagnostic accuracy for residual tumor compared with MR imaging. . . . . ***Page 1053***

^{82}Rb PET/CT in prostate cancer: Jochumsen and colleagues evaluate ^{82}Rb PET/CT as a diagnostic tool for quantitative tumor blood flow imaging in prostate cancer patients and as a noninvasive biomarker for tumor aggressiveness and monitoring in nonmetastatic prostate cancer. . . . . ***Page 1059***

Imaging biomarkers for ^{90}Y distribution: Schobert and colleagues identify baseline imaging features in patients with liver cancer that correlate with ^{90}Y distribution on postprocedural SPECT and predict tumor response to transarterial radioembolization. . . . . ***Page 1066***

Intraperitoneal ^{211}At in ovarian cancer: Hallqvist and colleagues present clinical outcomes and toxicity data in a long-term follow-up of a phase I trial with intraperitoneal α-particle therapy in epithelial ovarian cancer. . . . . ***Page 1073***

PET/MRI repeatability in pelvic tumors: Fraum and colleagues determine the test–retest repeatability of PET/MR imaging SUV and apparent diffusion coefficient metrics in solid tumors of the pelvis and compare these results with those from PET/CT. . . . . ***Page 1080***

Whole-body PET in pediatric lymphoma: Cerci and colleagues assess the incidence and clinical impact of lesions outside the "eyes to thighs" field of view in ^{18}F-FDG PET/CT staging and interim scans in pediatric lymphoma patients. . . . . ***Page 1087***

Metabolic tumor volume in lymphoma: Gallamini provides a brief road map for validation and standardization of metabolic tumor volume computation and previews a relevant article in this issue of *JNM*. . . . . . ***Page 1094***

Standardized MTV measurement: Barrington and Meignan report on discussions from the PET International Lymphoma and Myeloma Workshop and offer a proposal for performance of technical validation of metabolic tumor volume measurement to enable benchmark reference ranges. . . . . ***Page 1096***

Molecular imaging of nimotuzumab ADCs: Hartimath and colleagues use small-animal SPECT/CT and ex vivo distribution studies of antibody drug conjugates with PEGylated-maytansine to provide insights for evaluation of pharmacokinetics and normal tissue toxicity to determine dosing rates. . . . . ***Page 1103***

Healthy tissue and PCa PET tracers: Jansen and colleagues quantify uptake variability of prostate cancer tracers, including ^{68}Ga-PSMA, ^{18}F-DCFPyL, ^{18}F-FCH, and ^{18}F-FDHT, in healthy tissues and identify stable reference regions for PET interpretation. . . . . ***Page 1111***

PSMA PET/MR in recurrent PCa after HIFU: Burger and colleagues investigate whether ^{68}Ga-PSMA-11 can be used to localize recurrent disease with PET/MR in patients with discrepant findings after high-intensity focused ultrasound treatment for prostate cancer. . . . . ***Page 1118***

MC1R-targeted α-particle therapy: Tafreshi and colleagues report on preclinical development and testing of a novel melanocortin 1 receptor–targeted radiopharmaceutical, ^{225}Ac-DOTA-MC1RL, for α-particle therapy of uveal melanoma. ***Page 1124***

Perfusion scintigraphy in PE follow-up: Marconi and colleagues look at changes in pulmonary perfusion at 4 follow-up points within 1 y in patients with pulmonary embolism and elucidate factors predictive of complete or incomplete recovery of perfusion. . . . . ***Page 1134***

11β-HSD1–targeted brain imaging: Gallezot and colleagues detail the results of studies with ^{11}C-AS2471907 PET to image 11β-hydroxysteroid dehydrogenase type 1 enzyme availability in the human brain. . . . . ***Page 1140***

M_1 mAChR PET imaging in NHPs: Nabulsi and colleagues report on the synthesis and evaluation of ^{11}C-LSN3172176, targeting the M_1 muscarinic acetylcholine receptor, with PET imaging in nonhuman primates. . . . . ***Page 1147***

^{18}F-JNJ-64413739 P2X7 PET: Kolb and colleagues describe in vitro and in vivo preclinical studies with this ^{18}F-labeled PET ligand for imaging the P2X7 receptor in the brain. ***Page 1154***

^{18}F-labeled PSMA ligands: Kuo and colleagues evaluate a series of prostate-specific membrane–targeting probes and label them with ^{18}F in a single step for PET imaging of prostate cancer. . . . . ***Page 1160***

GluN2B and σ_1R PET: Haider and colleagues investigate the performance characteristics of the enantiomers of ^{11}C-Me-NB1, a recently reported PET imaging probe that targets the glutamate N2B subunit of *N*-methyl-D-aspartate receptors. . . . . ***Page 1167***

FcγRI binding and immuno-PET: Vivier and colleagues determine whether radioimmunoconjugates with truncated glycans exhibit altered binding to immune cells bearing Fc-γ-receptors and, in turn, improve in vivo performance on antibody-targeted PET imaging. . . . . ***Page 1174***

Deep learning in WB ToF PET/MRI: Hwang and colleagues propose a new deep learning–based approach to provide more accurate whole-body time-of-flight PET/MRI attenuation correction than is possible with the Dixon-based 4-segment method. . . . . ***Page 1183***